[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"advanced-solid-tumors-or-lymphomas\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:advanced-solid-tumors-or-lymphomas":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":5},"100521772","compassionate-use-study-of-nhwd-870-in-patients-with-advanced-solid-tumors-or-lymphomas-carrying-nut-rearrangement-100521772",false,"NCT06073938","Compassionate Use Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT Rearrangement","A Real-World Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT Rearrangement","Inclusion Criteria:\n\n1. Signing an informed consent form;\n2. Patients with advanced solid tumors or lymphomas definitively diagnosed by pathology;\n3. Age ≥18 and ≤75 years;\n4. Eastern Cooperative Oncology Group (ECOG) score physical status score of 0 to 1;\n5. Expected survival of \\>3 months;\n6. NUT positive confirmed by molecular testing.\n\nExclusion Criteria:\n\nSubjects who meet one or more of the following criteria will be excluded:\n\n1. Other serious complications (such as uncontrolled infection, myocardial infarction within 6 months, high blood pressure (≥ 160\u002F100mmHg) and thromboembolic disease that cannot be controlled by drug intervention, etc.);\n2. The adverse reactions of previous anti-tumor therapy have not been restored to CTCAE 5.0 ≤ Grade1 (except for hair loss, anemia and other toxicities judged by researchers to be unsafe);\n3. History of substance abuse;\n4. Inability to take drugs due to dysphagia (except for patients who receive nutrients through a gastric tube due to dysphagia), or conditions that the investigator determines seriously affect gastrointestinal absorption;\n5. Patients with a history of other serious systemic diseases who are judged by the investigator to be unsuitable for participating in clinical trials;\n6. Alcoholics or those who drink more than 28 units of alcohol per week (1 unit = 285 mL of beer or 25 mL of spirits or 1 glass of wine);\n7. Suffering from uncontrollable mental illness;\n8. Pregnant or lactating women, or patients of childbearing age (including male subjects) with pregnancy plans;\n9. Active hepatitis B (viral titer \\>103), hepatitis C or HIV ( );\n10. Long-term treatment with high-dose corticosteroids or other immunosuppressants, such as those who have undergone organ transplantation, or those who have received systemic glucocorticoids (such as prednisone\\> 10 mg\u002Fday or equivalent drugs) or other immunosuppressant therapy within 14 days before the first use of the study drug; Exceptions are given for topical, ocular, intra-articular, intranasal and inhaled corticosteroid therapy; short-term use of glucocorticoids for prophylaxis (e.g., prevention of contrast allergy);\n11. The investigator believes that the subject is not suitable to participate in this clinical study for other objective reasons.","ALL","18 Years","75 Years",{"count":20,"type":21},30,"ESTIMATED","OBSERVATIONAL","The NHWD-870 Phase I clinical trial evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics in patients with advanced tumors. The objectives of this retrospective study were to preliminarily evaluate the anti-tumor efficacy of NHWD-870 HCl in patients with advanced solid tumors or lymphomas and to preliminarily evaluate biomarkers associated with the efficacy of NHWD-870 HCl in the treatment of patients with advanced solid tumors or lymphomas, to provide a basis for identifying the enriched population for the late-stage trial.",[25],"Advanced Solid Tumors or Lymphomas","RECRUITING","2024-09-17",{"date":29,"type":30},"2024-09-19","ACTUAL",{"date":32,"type":30},"2022-09-20",{"date":34,"type":21},"2025-06-30",{"name":36,"class":37},"Hunan Province Tumor Hospital","OTHER"]